Neonatal respiratory distress syndrome (NRDS) is caused by deficiency of pulmonary surfactant (PS) in premature infants generally. But it is associated with gestational age, birthweight, asphyxia, caesarean birth, infection, use dexamethasone to mother before delivery, diabetic mother and fetus intrauterine hypoxia. Treated with ambroxol and dexamethasone to maternity before delivery may prevent the NRDS. High dose ambroxol, PS, continuous positive air-way pressure, high-frequency oscillatory ventilation, inhaled NO, liquid ventilation and extracorporeal membrane oxygenation may be used earlier to newborns after birth to avoid aggravation of the disease.
Objective: To observe the clinical efficiency of Medilac-Vita in children with neonatal jaundice. Methods: 112 cases of newborn with neonatal jaundice were randomly divided into treatment group and control group. All were treated with routine therapy. Oral Medilac-Vita was added to the treatment group. Clinical efficiency was observed by detection of transcautaneous bilirubin. Results: The level of transcautaneous bilirubin in treatment group was significantly lower than the control group. After 7 days of treatment, the effective rate and cure rate of the treatment group are obviously better than the control group. Conclusions: Moreover, the effect of Medilac-Vita in treatment of neonatal jaundice is better than routine treatment, it can reduce the serum bilirubin rapidly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.